Skip to content
PeptideAgent

Peptides for chronic pain: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Ziconotide (Prialt), a synthetic cone snail peptide delivered by an implanted intrathecal pump, is the only peptide FDA approved for pain, reserved for severe chronic pain that has failed other treatments. It reduced pain in three placebo controlled trials but carries a boxed warning for psychiatric and neurological effects. Peptides marketed for pain, such as BPC-157, have no human pain trials.

Evidence: Strongest: Human RCT evidence4 peptides gradedVerified: Verified Sep 23, 2026

Do peptides help with chronic pain?

4 peptides are graded for chronic pain on this page. The strongest grade is human RCT evidence, for ziconotide and ARA-290 (cibinetide). Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for chronic pain?

Multimodal care matched to the pain type: exercise and physical therapy, cognitive behavioral therapy, NSAIDs or acetaminophen for musculoskeletal pain, and duloxetine, pregabalin, or gabapentin for neuropathic pain; opioids only after nonopioid options, with careful risk review per the 2022 CDC guideline; interventional options, including intrathecal pumps, for refractory cases.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for chronic pain?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Chronic pain with evidence grades
PeptideEvidence for this useNote
ZiconotideEvidence: Human RCT evidencePain scores improved 14.7% to 53.1% versus 6.0% to 18.1% on placebo across three trials; requires an intrathecal pump; boxed warning for psychiatric and neurological effects. [1] [2] [6]
ARA-290 (cibinetide)Evidence: Human RCT evidenceImproved neuropathic pain scores in small trials in sarcoidosis and type 2 diabetes; not approved. [7]
BPC-157Evidence: Animal-only evidenceMarketed for joint and injury pain; rodent healing data only, with no human pain study. [8]
ThymulinEvidence: Animal-only evidenceA thymulin related peptide reduced inflammatory and neuropathic pain in rodents; no human pain study. [9]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for chronic pain?

Ziconotide and ARA-290 (cibinetide) have the strongest evidence among the peptides graded here, at human RCT evidence. Ziconotide: Pain scores improved 14.7% to 53.1% versus 6.0% to 18.1% on placebo across three trials; requires an intrathecal pump; boxed warning for psychiatric and neurological effects. ARA-290 (cibinetide): Improved neuropathic pain scores in small trials in sarcoidosis and type 2 diabetes; not approved. [1] [2] [6] [7]

Is any peptide FDA approved for chronic pain?

Ziconotide is an FDA approved drug, but an approval covers only the indications on that label, so check the label before assuming it applies to chronic pain. The other peptides graded here are not FDA approved. [1] [2] [6] [10]

Has any peptide been tested in a randomized trial for chronic pain?

Yes, for ziconotide and ARA-290 (cibinetide). Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2] [6] [7]

Sources

  1. [1]Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trialPubMed 14709577, 2004
  2. [2]Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trialPubMed 22151630, 2006
  3. [3]A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic painPubMed 16716870, 2006
  4. [4]Deer TR et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation 2017PubMed 28042904, 2017
  5. [5]CDC clinical practice guideline for prescribing opioids for pain, United States, 2022. MMWR Recomm Rep 2022PubMed 36327391, 2022
  6. [6]FDA prescribing information for Prialt (ziconotide intrathecal infusion), via DailyMedFDA, 2024
  7. [7]Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyPubMed 23168581, 2012
  8. [8]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationPubMed 21030672, 2011
  9. [9]Contribution of zinc and other metals to the biological activity of the serum thymic factorPubMed 6957870, 1982
  10. [10]Drugs@FDA: FDA-approved drugs databaseFDA